Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/12/09 09:46:39」(JST)

wiki en

Verteporfin (trade name Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.^[1]^[2]

Verteporfin is also used off-label for the treatment of central serous retinopathy.^[3]

Administration

Verteporfin is given intravenously, 15 minutes before laser treatment.^[1]

Contraindications

Porphyria.^[1]

Side effects

Most common side effects are blurred vision, headache, and local effects at the injection site. Also, photosensitivity; it is advised to avoid exposure to sunlight and unscreened lighting until 48 hours after the injection of verteporfin.^[1]

Interactions

None known. Verteporfin has no influence on the liver enzyme CYP3A4, which metabolises many pharmaceutical drugs.^[1]

References

^ ^a ^b ^c ^d ^e Verteporfin monograph
^ Scott, L. J.; Goa, K. L. (2000). "Verteporfin". Drugs & aging 16 (2): 139–146; discussion 146–8. doi:10.2165/00002512-200016020-00005. PMID 10755329. edit
^ Adelman, R.; Adelman, R. A. (2013). "Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy". Clinical Ophthalmology 7: 1867–1875. doi:10.2147/OPTH.S32177. PMC 3788817. PMID 24092965. edit

External links

Novartis website for Visudyne
Research into using verteporfin to treat pancreatic cancer

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 加齢黄斑変性：治療および予防 age related macular degeneration treatment and prevention
2. 眼ぶどう膜および結膜の悪性黒色腫 uveal and conjunctival melanomas

English Journal

Photosensitizers and Photodynamic Therapy: Verteporfin.

Battaglia Parodi M, La Spina C, Berchicci L, Petruzzi G, Bandello F.
Developments in ophthalmology.Dev Ophthalmol.2016;55:330-6. doi: 10.1159/000434704. Epub 2015 Oct 26.
Photodynamic therapy (PDT) is a phototherapy in which a photosensitive dye is injected into a peripheral vein and activated by light in order to occlude choroidal vessels or change their permeability. PDT has been largely applied in the treatment of choroidal neovascularization (CNV), especially CNV
PMID 26501167

Central Serous Chorioretinopathy Treatments: A Mini Review.

Iacono P, Battaglia Parodi M, Falcomatà B, Bandello F.
Ophthalmic research.Ophthalmic Res.2015 Dec 1;55(2):76-83. [Epub ahead of print]
Central serous chorioretinopathy (CSC) is a retinal disorder that primarily affects young (20- to 50-year-old) white men, although it is seen occasionally in older patients and females. CSC is characterized by avascular focal leakage through the retinal pigment epithelium (RPE), resulting in serous
PMID 26619293

COMPARISON OF HALVING THE IRRADIATION TIME OR THE VERTEPORFIN DOSE IN PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.

Shiode Y1, Morizane Y, Kimura S, Hosokawa M, Kawata T, Doi S, Hosogi M, Fujiwara A, Shiraga F.
Retina (Philadelphia, Pa.).Retina.2015 Dec;35(12):2498-504. doi: 10.1097/IAE.0000000000000621.
PURPOSE: To compare the efficacy and safety of photodynamic therapy using reduced irradiation time or reduced verteporfin dose for chronic central serous chorioretinopathy.METHODS: Between April 2011 and December 2013, 45 eyes with chronic central serous chorioretinopathy (43 consecutive patients) w
PMID 26035398

Japanese Journal

視力不良例の加齢黄斑変性に対する光線力学療法

平野彩,新夕愛,北善幸 [他]
東邦医学会雑誌 57(6), 368-373, 2010-11-00
NAID 40017407689

Impact of Photodynamic Therapy on Quality of Life of Patients with Age-Related Macular Degeneration in Korea

Kim Jinhyun,Kwak Hyung Woo,Lee Won Ki [他],KIM Ha Kyoung
Japanese journal of ophthalmology 54(4), 325-330, 2010-07-01
NAID 10027204574

ベルテポルフィンを用いた光線力学的療法後に一過性の肝胆道系酵素上昇を認めた1例

松本行弘
眼科臨床紀要 = Folia Japonica de ophthalmologica clinica 3(3), 244-247, 2010-03-15
NAID 10030250200

「ベルテポルフィン」

Verteporfin
Systematic (IUPAC) name
	3-[(23S,24R)-14-ethenyl-5-(3-methoxy-3-oxopropyl)-22,23-bis(methoxycarbonyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid
Clinical data
Trade names	Visudyne
AHFS/Drugs.com	monograph
MedlinePlus	a607060
Pregnancy cat.	US: C;
Legal status	US: ℞-only;
Routes	Intravenous
Identifiers
CAS number	129497-78-5
ATC code	S01LA01
PubChem	CID 5362420
DrugBank	DB00460
ChemSpider	21106402
UNII	0X9PA28K43
KEGG	D01162
ChEBI	CHEBI:60775
ChEMBL	CHEMBL2218885
Chemical data
Formula	C41H42N4O8
Mol. mass	718.794 g/mol
	SMILES COC(=O)[C@@H]2C(=C\C=C3\c1cc6nc(cc5nc(cc4nc(cc(n1)[C@]23C)C(/C)=C4/CCC(=O)OC)c(CCC(O)=O)c5C)C(/C=C)=C6/C)/C(=O)OC;
	InChI InChI=1S/C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h9-10,13,16-19,38,43,45H,1,11-12,14-15H2,2-8H3,(H,46,47)/b31-16-,33-18-,34-17-,35-19-/t38-,41+/m0/s1 ; Key:ZCQHFRFEJXRZDF-YWANUUMDSA-N ;
(what is this?) (verify)